Dimensional Fund Advisors LP Acquires 48,952 Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL)

Dimensional Fund Advisors LP boosted its position in shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) by 43.9% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 160,577 shares of the company’s stock after acquiring an additional 48,952 shares during the period. Dimensional Fund Advisors LP owned 0.37% of Werewolf Therapeutics worth $392,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. Janus Henderson Group PLC bought a new stake in Werewolf Therapeutics in the 1st quarter valued at $10,922,000. Vanguard Group Inc. raised its stake in shares of Werewolf Therapeutics by 26.8% during the 1st quarter. Vanguard Group Inc. now owns 1,107,347 shares of the company’s stock worth $7,176,000 after acquiring an additional 233,909 shares in the last quarter. Acadian Asset Management LLC raised its stake in shares of Werewolf Therapeutics by 119.8% during the 1st quarter. Acadian Asset Management LLC now owns 172,883 shares of the company’s stock worth $1,119,000 after acquiring an additional 94,212 shares in the last quarter. Bank of New York Mellon Corp bought a new position in shares of Werewolf Therapeutics during the 2nd quarter worth approximately $165,000. Finally, Rhumbline Advisers acquired a new position in Werewolf Therapeutics during the 2nd quarter valued at approximately $79,000. Hedge funds and other institutional investors own 64.84% of the company’s stock.

Werewolf Therapeutics Price Performance

Shares of NASDAQ HOWL opened at $1.96 on Tuesday. Werewolf Therapeutics, Inc. has a 52 week low of $1.57 and a 52 week high of $8.19. The stock has a market capitalization of $85.17 million, a price-to-earnings ratio of -1.80 and a beta of 0.45. The firm has a 50-day simple moving average of $2.09 and a 200-day simple moving average of $3.42. The company has a quick ratio of 12.13, a current ratio of 12.13 and a debt-to-equity ratio of 0.24.

Werewolf Therapeutics (NASDAQ:HOWL) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.05). The firm had revenue of $1.14 million for the quarter, compared to analyst estimates of $2.00 million. Werewolf Therapeutics had a negative return on equity of 48.25% and a negative net margin of 578.80%. On average, equities analysts predict that Werewolf Therapeutics, Inc. will post -1.64 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on HOWL shares. JMP Securities reaffirmed a “market outperform” rating and issued a $12.00 price objective on shares of Werewolf Therapeutics in a report on Wednesday, June 26th. HC Wainwright reiterated a “buy” rating and issued a $15.00 target price on shares of Werewolf Therapeutics in a research report on Tuesday, July 2nd.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.